Nurulimab (BCD-145) is an anti-cytotoxic T lymphocyte antigen-4 (anti-CTLA-4) human monoclonal antibody. Nurulimab can be can be used in research of melanoma[1].
References
[1] International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 34, No. 1, 2020.
